Intervention Protocol

You have free access to this content

Glycopyrronium bromide for chronic obstructive pulmonary disease

  1. Joseph P Burke1,*,
  2. Jacques G Eastment1,
  3. Rayleen V Bowman1,2,
  4. Kwun M Fong1,2,
  5. Ian A Yang1,2

Editorial Group: Cochrane Airways Group

Published Online: 31 OCT 2013

DOI: 10.1002/14651858.CD010798


How to Cite

Burke JP, Eastment JG, Bowman RV, Fong KM, Yang IA. Glycopyrronium bromide for chronic obstructive pulmonary disease (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No.: CD010798. DOI: 10.1002/14651858.CD010798.

Author Information

  1. 1

    The University of Queensland, School of Medicine, Brisbane, Australia

  2. 2

    The Prince Charles Hospital, Thoracic Medicine Program, Brisbane, Queensland, Australia

*Joseph P Burke, School of Medicine, The University of Queensland, Brisbane, Australia. joseph.burke@uqconnect.edu.au.

Publication History

  1. Publication Status: New
  2. Published Online: 31 OCT 2013

SEARCH

References

Additional references

Adair 2012
  • Adair T, Hoy D, Dettrick Z, Lopez AD. 100 years of mortality due to chronic obstructive pulmonary disease in Australia: the role of tobacco consumption. International Journal of Tuberculosis and Lung Disease 2012;16:1699-705.
Appleton 2006
  • Appleton S, Jones T, Poole P, Lasserson TJ, Adams R, Smith B, et al. Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD006101]
Beeh 2002
Belmonte 2005
  • Belmonte KE. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proceedings of the American Thoracic Society 2005;2:297-304.
Buhl 2012
  • Buhl R, Banerji D. Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD. International Journal of Chronic Obstructive Pulmonary Disease 2012;7:729-41.
Chong 2012
Cooper 2006
  • Cooper N, Walker I, Knowles I. NVA237 has similar efficacy as tiotropium bromide against methacholine-induced bronchoconstriction and less systemic effect on cardiovascular variables in an anaesthetized rabbit model [Abstract]. European Respiratory Journal 2006;28(Suppl 50):P2544.
Fuder 1993
GOLD 2013
  • Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD. http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html (accessed 17 May 2013).
Gomez 1995
  • Gomez A, Bellido I, Sanchez de la Cuesta F. Atropine and glycopyrronium show similar binding patters to M(2) (cardiac) and M(3) (submandibular-gland) muscarinic receptors subtypes in the rat. British Journal of Anaesthesia 1995;74:549-52.
Haddad 1999
Halbert 2006
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Hogg 2009
Kim 2008
  • Kim V, Rogers TJ, Criner GJ. New concepts in the pathobiology of chronic obstructive pulmonary disease. Proceedings of the American Thoracic Society 2008;5:478-85.
Kim 2013
  • Kim V, Criner GJ. Chronic bronchitis and chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2013;187:228-37.
Lozano 2012
  • Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095-128.
McKenzie 2012
  • McKenzie DK, Abramson M, Crockett AJ, Dabscheck E, Glasgow N, Jenkins S, et al. The COPD-X Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease 2012. Version 2.34 November 2012. Lung Foundation Australia and the Thoracic Society of Australia and New Zealand. Available from www.copdx.org.au/.
Meurs 2013
  • Meurs H, Dekkers BG, Maarsingh H, Halayko AJ, Zaagsma J, Gosens R. Muscarinic receptors on airway mesenchymal cells: novel findings for an ancient target. Pulmonary Pharmacology & Therapeutics 2013;26:145-55.
Murray 2012
  • Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2197-223.
Review Manager 2013
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2013.
Roffel 1990
  • Roffel AF, Elzinga CR, Zaagsma J. Muscarinic M3 receptors mediate contraction of human central and peripheral airway smooth muscle. Pulmonary Pharmacology 1990;3:47-51.
Sykes 2012
  • Sykes DA, Dowling MR, Leighton-Davies J, Kent TC, Fawcett L, Renard E, et al. The Influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium. Journal of Pharmacology and Experimental Therapeutics 2012;343:520-8.
Trifilieff 2007
  • Trifilieff A, Cope N, Bohacek B, Mazzoni L, Collingwood S. The inhaled muscarinic receptor antagonist, glycopyrrolate, has a favorable side effect profile in a Brown Norway rat lung function model when compared with tiotropium. Chest 2007;132(4_MeetingAbstracts):530a.
Vogelmeier 2011
  • Vogelmeier C, Verkindre C, Cheung D, Galdiz J B, Guclu S Z, Spangenthal S, et al. Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Pulmonary Pharmacology & Therapeutics 2011;23:438-44.
Wedzicha 2012
  • Wedzicha JA, Decramer M, Seemungal TA. The role of bronchodilator treatment in the prevention of exacerbations of COPD. European Respiratory Journal 2012;40:1545-54.
ZuWallack 2004
  • ZuWallack RL, Haggerty MC, Jones P. Clinically meaningful outcomes in patients with chronic obstructive pulmonary disease. American Journal of Medicine Supplements 2004;117(Suppl 12A):49S-59S.